Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization

Human Reproduction

Volumn 11, Issue 11, 1996, Pages 2400-2404

  Balasch, Juan ^a,b   Fábregues, Francisco ^a   Creus, Montserrat ^a   Moreno, Vicenta ^a   Puerto, Bienvenido ^a   Peñarrubia, Joana ^a   Carmona, Francisco ^a   Vanrell, Juan A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Highly purified FSH; IVF; Ovarian stimulation; Pure FSH; Urofollitrophins

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; NEO FERTINORM; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PURITY; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OOCYTE; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030458742     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.humrep.a019123     Document Type: Article

References (22)

1. Balasch, J., Jové, I.C., Moreno, V. et al. (1992) The comparison of two gonadotrophin-releasing hormone agonists in an in vitro fertilization program. Fertil. Steril., 58, 991-994.
2. Balasch, J., Miró, F., Burzaco, I. et al. (1995) The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum. Reprod., 10, 1678-1683.
3. Dahl Lyons, C.A., Wheeler, C.A., Frishman, G.N. et al. (1994) Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum. Reprod., 9, 792-99.
4. Daya, S., Gunby, J., Hughes, E.G. et al. (1995) Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: a meta-analysis. Fertil Steril., 64, 347-354.
5. Filicori, M., Flamigni, C., Cognigno, G.E. et al. (1996) Different gonadotrophin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertil. Steril., 65, 387-393.
6. Fried, G., Harlin, J., Csemickzy, G. and Wramsby, H. (1996) Controlled ovarian stimulation using highly purified FSH results in a lower serum oestradiol profile in the follicular phase as compared with HMG. Hum. Reprod., 11, 474-477.
7. Golan, A., Ron-El, R., Herman, A. et al. (1989) Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv., 44, 430-440.
8. Hamilton-Fairley, D., Kiddy, D., Watson, H. et al. (1991) Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum. Reprod., 6, 1095-1099.
9. Hedon, B., Out, H.J., Hugues, J.N. et al. (1995) Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Hum. Reprod., 10, 3102-3106.
10. Hillier, S.G. (1994) Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum. Reprod., 9, 188-191.
11. Howles, C.M., Loumaye, E., Giroud, D. and Luyet, G. (1994) Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum. Reprod., 9, 424-430.
12. Hughes, E.G., Fedorkow, D.M., Daya, S. et al. (1992) The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intraFallopian transfer: a meta-analysis of randomized controlled trials. Fertil. Steril., 58, 888-896.
13. Hull, M.G.R., Armatage, R.J. and McDermott, A. (1994) Use of follicle-stimulating hormone alone (urofollitropin) to stimulate the ovaries for assisted conception after pituitary desensitization. Fertil. Steril., 62, 997-1003.
14. Meldrum, D.R. (1993) Ovarian stimulation for assisted reproductive technology. Infertil. Reprod. Med. N. Am., 4, 643-652.
15. Penzias, A.S., Shamma, F.N., Gutmann, J.N. et al. (1992) Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial. Obstet. Gynecol., 79, 739-742.
16. Sagle, M.A., Hamilton-Fairley, D., Kiddy, D.S. and Franks, S. (1991) A comparative, randomized study of low-dose human menopausal gonadotrophin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertil. Steril., 55, 56-60.
17. Shoham, Z., Jacobs, H.S. and Insler, V. (1993) Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil. Steril., 59, 1153-1161.
18. Simoni, M. and Nieschlag, E. (1995) FSH in therapy: physiological basis, new preparations and clinical use. Reprod. Med. Rev., 4, 163-177.
19. Strickler, R.C., Radwanska, E. and Williams, D.B. (1995) Controlled ovarian hyperstimulation regimens in assisted reproductive technologies. Am. J. Obstet. Gynecol., 172, 766-773.
20. Tan, S.L., Maconochie, N., Doyle, P. et al. (1994) Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotrophin-releasing hormone agonist buserelin. Am. J. Obstet. Gynecol., 171, 513-520.
21. Veeck, L.L. (1986) Atlas of the Human Oocyte and Early Conceptus. Williams and Wilkins, Baltimore.
22. Westergaard, L.G., Erb, K., Laursen, S. et al. (1996) The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Hum. Reprod., 11, 1209-1213.